Objective: To estimate the relative inpatient costs of hospital-acquired conditions. Methods: Patient level costs were estimated using computerized costing systems that log individual utilization of inpatient services and apply sophisticated cost estimates from the hospital's general ledger. Occurrence of hospital-acquired conditions was identified using an Australian 'condition-onset' flag for diagnoses not present on admission. These were grouped to yield a comprehensive set of 144 categories of hospitalacquired conditions to summarize data coded with ICD-10. Standard linear regression techniques were used to identify the independent contribution of hospital-acquired conditions to costs, taking into account the casemix of a sample of acute inpatients (n 5 1,699,997) treated in Australian public hospitals in Victoria (2005/ 06) and Queensland (2006/07).
Introduction
Priority-setting for patient safety programmes needs to take multiple factors into account: the frequency of the events leading to patient harm, the severity of outcomes, the absolute numbers of patients harmed, the evidencebase for the success of preventive efforts, the feasibility and acceptability of such interventions, and the economic losses due to these events. One large contributor to economic loss is the additional costs of hospital care attributable to adverse events, over and above the costs of treating the patient's diagnoses on admission. 1 Most efforts to use hospital administrative data to characterize patient complications have been premised on public reporting. This expectation has led to considerable investment in risk-adjustment approaches 2 -4 and to focusing research effort on complications deemed to be preventable. 5 Using these tools, which focus on predetermined conditions of interest, it is not possible to estimate the relative contribution of all hospital-acquired illnesses and injuries. Yet, estimation of 'preventability' changes as new scientific evidence of causal factors emerges, together with new research on effective prevention.
Zhan and Miller estimated additional costs of 18 types of 'medical injury'. 1 More recently, Shreve et al. have published estimates of the costs of 50 classes of 'medical error', 6 building on Layde et al.'s earlier classification of inpatient events. 7 These USA studies rely on billed charges to quantify costs and have not had access to information to distinguish pre-hospitalization from inpatient events, relying instead on sets of 'external cause of injury' codes to identify adverse outcomes.
Two Australian studies have attempted to quantify the costs of hospital-acquired conditions. The first applied DRG cost-weights to a sample of patient records from the Quality in Australian Health Care study to estimate the costs of adverse events. 8, 9 The second used costing data from an Australian state public hospital system to estimate the additional costs of adverse events. 10 The weaknesses of this study in setting priorities for prevention programmes, however, are that it resorted to ad hoc groupings of hospital-acquired diagnosis codes, considered only the first-recorded diagnosis of an in-hospital complication, and used cost data from only Victoria.
The recently reported classification of hospitalacquired diagnoses (CHADx) allows us to characterize complications of hospital care in a systematic and reproducible way. 11 It contains 17 major CHADx categories and 144 sub-categories, using a condition onset flag to distinguish pre-existing comorbidities from conditions arising in hospital. In this paper we describe the use of the CHADx to estimate the cost per case and total financial burdens of inpatient complications to the public hospital systems of two Australian states, representing nearly 40% of the Australian population.
Methods
We used secondary analysis of routine hospital data on patient-level diagnoses, procedures and costs. Table 1 describes the de-identified patient-level data on AU$1.7 million costed public hospital episodes analysed.
Diagnosis codes
Diagnosis data were abstracted from patient records by trained professional coders or health information managers; we truncated the records at 50 diagnosis fields. In both states, data are routinely edited by the respective health departments against published standards for plausible code combinations, and both states conduct audits of patient records from public hospitals. 12, 13 In Victoria, financial penalties are applied for funded hospitals with exceptional rates of coding error. 11 National coding standards require that all diagnoses monitored or treated during the admission be recorded. 14 
Diagnosis onset flag
Victorian coding has included information on the timing of diagnoses since at least 1980. For application of a 'C' prefix (indicating a 'complication') the coder must ascertain that there was no evidence of the condition existing prior to admission, that is, the C-prefix is used only for a diagnosis arising after admission. Queensland adopted a similar numeric 'diagnosis onset flag' in July 2006. Both distinguish pre-existing co-morbidities from hospital-acquired conditions, and incident diagnoses (arising during the current episode) from those in readmission episodes. 15 The more recent adoption of onset-flagging by Queensland meant that only one year (2006/07) of data was available. Flagging was evaluated using a recently developed algorithm to identify chronic and congenital conditions that are unlikely to be hospital-acquired. 16 
Cost and other variables in OSL model
State health authorities in both Victoria and Queensland collect annual patient-level costs from their public hospitals. Costs are estimated using computerized clinical costing systems that identify the costs of hospital care for individual patients. 17 These costs are subjected to data quality checks before calculation of cost weights for case-mix based hospital funding, including re-submission of cases with missing data to the originating hospital. The 45 hospitals from Victoria are larger urban hospitals, accounting for 86.4% of weighted (for complexity) inpatient activity for 1 July 2005 to 30 June 2006.
Later data were requested from Queensland because it was the second state in Australia to flag hospital-acquired diagnoses, beginning only in the 2006/07 FY. The Queensland cost data are collected from all hospitals in the state for submission to the National Hospital Cost Data Collection. In this study, we use only those costed episodes evaluated and accepted for inclusion in the national dataset (n ¼ 616,153 cases in 23 hospitals).
Cost per case includes the costs of treating the primary diagnosis (reason for admission), any additional costs attributable to co-morbidities, and the costs of any hospital-acquired diagnoses.
Uncomplicated treatment cost is that portion of each patient's measured cost per case attributable to their principal diagnosis and co-morbidities. This is calculated for each DRG as the mean of all episodes with no CHADx. Mean corrected treatment cost is that portion of each patient's measured cost per case remaining after subtracting the uncomplicated treatment cost for the DRG assigned to the episode. These costs are used as the dependent variable in linear regression analyses to estimate the marginal effects of each CHADx. The total cost is based on the costs attributable to a particular CHADx based on the marginal CHADx treatment cost multiplied by the number of instances of the CHADx in the study database.
Same day patients is a dummy variable, equal to one for patients treated in hospital on a 'same day' basis, and zero for multi-day patients was used. The Australian DRG version, AR-DRGs, 18 incorporates all inpatient episodes, including same day surgery and other procedures classed as 'ambulatory' in other classification systems. Death in hospital is a dummy variable equal to one if the patient dies in hospital, and zero otherwise, to control for any costs associated with end-of-life treatment that might distort estimates of costs for some hospital-acquired conditions.
Analysis
Standard linear regression was used to investigate the relationship between the cost of hospitalization and adverse events, after controlling for other covariates. Specification tests were applied to verify the choice of variables, and a heteroskedasticity test was applied to test the assumption of constant variance in regression analyses.
Since our data represent a relatively large sample (1.7 million observations), standard regressions can be used to produce robust and consistent results in spite of the fact that the cost data may not satisfy the normality assumption. 19 Untransformed data allow the expression of results in easily-interpretable dollar terms.
Results
The full results from our OLS model are shown in Appendix 1 (available online only at: www.jhsrp.rsmjournals.com/cgi/content/full/16/3/141/DC1). As expected, the majority of CHADx dummy variables have positive and significant parameter estimates, suggesting that they consistently add cost compared with uncomplicated episodes in the same DRG. The costs of same day episodes and those episodes where the patient dies in hospital are significantly lower compared with other episodes. Our model achieved an adjusted R 2 of 0.193. Table 2 reports the ten CHADx that generate the highest additional costs per episode. These are generally low volume diagnoses with very costly consequences, the exception being septicaemia, with both high per episode costs and reasonably high volume of cases. Two of the top ten are drug resistant infections (Methicillin-resistant Staph aureus and Vancomycin or other drug-resistant infections). These and others in the top ten, such as wound disruption/dehiscence and in-hospital falls resulting in hip fracture feature in most prevention/ patient safety programmes. Table 3 reports the top ten CHADx in terms of additional system costs ( per episode by the number of instances). Septicaemia heads this list because it is both costly per episode and relatively frequent. The high volume of cases of electrolyte disorders not associated with dehydration results in a relatively low-cost complication (AU$1,305 per episode) appearing in the top ten in terms of total system cost impact.
Our econometric model produced 18 negative coefficients of which 10 were statistically significant. Two of these were associated with anaesthesia, two with cardiac diagnoses, and six with childbirth (see Appendix 1). It is not clear why this might be the case, although it is likely that the negative coefficients reflect complex interactions between the individual CHADx when they both occur within the same admission. Alternatively, some CHADx may truly be cost reducing in any single episode.
We have factored the negative values into our estimates of total system costs. Although statistically significant, the low frequencies resulted in only a small effect on total cost, and we do not believe that the negative coefficients compromise our ability to interpret findings for the majority of CHADx. In total, hospital-acquired diagnoses add AU$790 million to the costs of inpatient care in the two states analysed here, representing 14.8% of total expenditures and additional costs of 17.3%.
Discussion
Patient safety programmes are usually initiated with little or no evaluation of priorities. More rational priority-setting would involve evaluation of several dimensions of the problem. The expected benefits for patient survival and quality of life of preventing particular kinds of hospital-acquired illness and injury must be considered. Evidence about the effectiveness of potential interventions in reducing the rate of such complications and the relative costs of introducing such programmes must also be considered, 20 and for research priorities, the expected value of perfect information.
Warburton has argued that patient safety interventions should meet the same cost-effectiveness criteria as other medical interventions. 21 The CHADx estimates reported here provide the basis on which the costeffectiveness of interventions to reduce rates of these common complications could be evaluated. Expressed as an index (using the mean cost per case as denominator), our results could be extrapolated to comparable hospitals and health care systems.
This study provides for the first time estimates of the relative cost of patient safety problems across the spectrum of patient harm. It addresses the problem highlighted by Runciman that mundane complications of care are often overlooked when priorities for patient safety interventions are evaluated. 22 Our analysis suggests that septicaemia, complications of cardiac and vascular implants (excluding septicaemia), acute lower respiratory infections (including influenza and pneumonia), urinary tract infections, and pressure ulcers represent the highest system cost complications. Most of these complications are common and, if not preventable in every case, are amenable to reduction in their rates.
Pressure ulcers are already a frequent target of prevention programmes because of their implications for protracting the length of stay but their financial costs may not have been fully appreciated. Other complications, however, are not so commonly recognized as resulting in high per case costs including the postprocedural endocrine disorders and complications of surgical implants. Better understanding of the financial burden of these diagnoses can help make the business case for greater investment in research on how best to prevent them and for evidence-based interventions. 23 Some of these adverse events are apparently mundane but events such as hospital-acquired gastroenteritis and constipation do not just cost the health system substantial amounts but also represent patient discomfort, inconvenience and potential loss of income due to an extended stay. Prevention of mundane events is rarely prioritized and often the research does not even exist to enable design of effective prevention or reduction programmes.
Our findings are subject to a number of limitations. They are clearly dependent on the quality of coding and prefixing of codes in hospitals. We consider the quality assurance programmes for inpatient data in the two states to be robust but we have not undertaken verification by parallel prospective data collection or independent chart review. In Victoria, cost data used were from one year prior to the Queensland data. Because our purpose was not comparative between the two systems, the period was one of low general inflation, observed cost differences between the two systems were small, and other sources of variation in the sample were large, we did not convert the data to a single price year.
Our use of linear regression assumes that episodes with multiple CHADx reflect random combinations of complications. Clinical reasoning suggests, however, that some CHADx may frequently occur together. To the extent that clustering exists, it may distort some of the coefficient-based CHADx costs reported here. We are currently undertaking work to better understand underlying syndromes of these diagnoses when they occur together, particularly in maternity episodes.
The cost data used in the study are not normally distributed, perhaps leading to concern that our analysis strategy should have involved log transformation of the data. We note that normality is a sufficient, but not a necessary, condition for application of ordinary least squares regression, particularly when samples are sufficiently large. Lumley et al. support this strategy, demonstrating that samples with less than 500 observations can provide unbiased estimates. 19 We believe that our data, which contains approximately 1.7 million observations, comfortably satisfies this criterion, and that policy uses of the findings are better served by interpretable cost estimates.
Earlier models tested in this study included a term for patient age and higher order polynomials of age as alternatives to a linear specification of the relationship of age and costs. While age variables were found to be significant predictors of increased treatment cost (taking the DRG into account), we have omitted them from the final model for policy reasons. It is certainly true that older patients are more vulnerable to hospital-acquired conditions. 24 If CHADx costs were to be adjusted for the patient's age through inclusion in the model, this would reduce the cost estimates for any CHADx that disproportionately affects older people and perhaps their priority for quality improvement efforts. It would be possible to re-weight each CHADx treatment cost using the appropriate coefficients for the distribution of patients' age in the CHADx but this is more cumbersome than simply leaving any age-related additional costs in the CHADx coefficient.
Patient safety efforts frequently focus on dramatic but rare complications with very serious patient harm. Useful information to reduce morbidity across the severity spectrum requires a comprehensive list of events (preventable or not with current clinical knowledge). Adding an economic dimension to priority-setting could result in changes to the priorities of patient safety programmes and would allow for cost-utility evaluation of existing prevention programmes. Such information may suggest future research directions, including study of causes and solutions for mundane adverse events that cause patient harm and increase inpatient costs.
